What Researchers Did
The researchers looked back at the records of 115 people with sudden hearing loss of unknown cause and compared two treatments: hyperbaric oxygen (HBO) and pentoxifylline infusions.
What They Found
This retrospective study of 115 patients with idiopathic sudden hearing loss found larger hearing gains in the 51 patients treated mainly with HBO at 2.8 bar than in the 64 patients given pentoxifylline infusions. Average hearing improved by 46.35 dB hearing level (SD 18.58) with HBO and by 21.48 dB hearing level (SD 13.5) with pentoxifylline, with p less than 0.001. Hearing returned to normal values in 24 of 51 HBO patients (47.1%) and 4 of 64 pentoxifylline patients (6.2%). Partial recovery was seen in 8 of 64 pentoxifylline patients (12.5%), while 21 of 51 HBO patients (41.2%) improved to a mild persistent hearing loss.
What This Means for Canadian Patients
For people with sudden hearing loss of unknown cause, this study reports better hearing results in the group treated with HBO than in the group given pentoxifylline. The patients were not randomly assigned to treatment, so the groups may have differed in ways the abstract does not describe. The authors say more prospective clinical trials are needed to confirm how well HBO works.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The study was retrospective, with patients who were not randomly assigned to treatment, so the abstract's comparison cannot show that HBO caused the better results, and the authors themselves call for prospective trials.